18892111. NEUTROPHIL SUPPRESSION AS PRECONDITIONING TO INCREASE ONCOLYTIC BACTERIAL THERAPY (The Johns Hopkins University)
NEUTROPHIL SUPPRESSION AS PRECONDITIONING TO INCREASE ONCOLYTIC BACTERIAL THERAPY
Organization Name
Inventor(s)
Renyuan Bai of Baltimore MD (US)
Verena Staedtke of Baltimore MD (US)
NEUTROPHIL SUPPRESSION AS PRECONDITIONING TO INCREASE ONCOLYTIC BACTERIAL THERAPY
This abstract first appeared for US patent application 18892111 titled 'NEUTROPHIL SUPPRESSION AS PRECONDITIONING TO INCREASE ONCOLYTIC BACTERIAL THERAPY
Original Abstract Submitted
Provided herein are methods for increasing the therapeutic efficiency of oncolytic bacterial therapeutics. Bacterial oncolytic therapies, especially the ones targeting tumor hypoxia such as -NT, often encounter incomplete tumor clearance in less hypoxic tumoral areas and severe inflammatory reactions. In this study, we explored immune-modulating preconditioning to suppress the host neutrophils and significantly enhanced the antitumor efficacy of -NT in animal models, including an orthotopic brain tumor model in rabbits. The optimized preconditioning agent, hydroxyurea, is clinically approved and -NT has demonstrated manageable safety and promising antitumor responses in clinical trials. Thus, the proposed preconditioning of neutrophil suppression is readily translatable to patients undergoing -NT trials or other oncolytic biologic therapies and could improve outcome.